Halberd（HALB）株式概要バイオテクノロジー企業であるハルバード・コーポレーションは、神経変性疾患の治療法を開発している。 詳細HALB ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析最新の財務報告は1年以上前のものである US市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( $822K )過去1年間で株主の希薄化が進んだ すべてのリスクチェックを見るHALB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.00113.6k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-2m7k2016201920222025202620282031Revenue US$6.9kEarnings US$1.3kAdvancedSet Fair ValueView all narrativesHalberd Corporation 競合他社LakeShore BiopharmaSymbol: OTCPK:LSBC.FMarket cap: US$1.6mSilexion TherapeuticsSymbol: NasdaqCM:SLXNMarket cap: US$962.6kOnconetixSymbol: NasdaqCM:ONCOMarket cap: US$270.2kPropanc BiopharmaSymbol: NasdaqCM:PPCBMarket cap: US$1.4m価格と性能株価の高値、安値、推移の概要Halberd過去の株価現在の株価US$0.001152週高値US$0.00352週安値US$0.0007ベータ01ヶ月の変化17.02%3ヶ月変化-31.25%1年変化-54.17%3年間の変化-87.91%5年間の変化-96.33%IPOからの変化-98.90%最新ニュースお知らせ • Oct 27Halberd Corporation Successfully Demonstrates Its Proprietary Breakthrough AI Technology for Behavioral Analysis PlatformHalberd Corporation announced the successful completion of a technical feasibility demonstration for NeuroSense AI, its proprietary behavioral intelligence platform in development. The live demonstration, conducted Thursday before key stakeholders, validated the platform's core technological approach and confirmed the feasibility of multi-modal behavioral analysis employing advanced artificial intelligence. In a live demonstration before clinical advisors and company leadership, the NeuroSense AI development team successfully showcased the platform's capacity to: Capture and process real-time behavioral data with professional-grade accuracy; Extract multiple behavioral features simultaneously (vocal patterns, energy levels, temporal characteristics); Generate automated behavioral assessments and visualizations; Demonstrate integration readiness with Claude AI for advanced pattern interpretation and capacity to demonstrate deviations from pre-establish norms. Technology Validation Milestone: The successful demonstration represents a critical development milestone, confirming that: Core Technologies Are Proven: The platform leverages commercially available, enterprise-grade technologies including Claude AI (Anthropic), industry-standard audio processing libraries, and cloud-native architecture patterns. Real-Time Processing Works: The system demonstrated capability to process behavioral data and generate analysis in real-time, a critical requirement for continuous monitoring applications.お知らせ • May 28Halberd Corporation & Athena Telemedicine Partnership, LLC Announce Clinical Study UpdatesHalberd Corporation in cooperation with Athena Telemedicine Partners, LLC, announced astounding clinical efficacy for patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease. previously found that patent-pending LDX medication is an incredibly ubiquitous compound that has powerful applications in the management of addiction, chronic inflammatory disorders, neurological disorders, pain management and represents a multibillion-dollar market potential. The problem: As of recent estimates, approximately 850 million people worldwide suffer from some form of kidney disease, including chronic kidney disease (CKD), acute kidney injury (AKI), and end-stage kidney failure. International Society of Nephrology Chronic Kidney Disease (CKD): In 2021, there were approximately 673.7 million cases of CKD globally. CKD is characterized by abnormalities in kidney structure or function lasting for more than three months and is a leading cause of kidney failure. Frontiers. Unresponsive to large doses of multiple medications, including Gabapentin, she was placed on LDX and a custom CBD nutraceutical. For the first time in five years, she became almost immediately symptom free. However, LD stopped the LDX based on physician input, and had a recurrence of her symptoms. She was hospitalized for hypertension and stabilized, a significant reduction in medications prescribed ensued, including Gabapentin, and as a result her neuropathy and pruritic symptoms reappeared. She was started on LDX again, but under a titrated dose response protocol that is patent pending, and immediately found relief of both the pain and itching. The company will be offering a 90-day trial for clinicians dealing with dialysis patients on a safety and proof of efficacy FDA study for LDX. platform involves a very low dose initiation and progressive introduction of LDN and methocarbamol with natural cinnamon as a filler to a traditional therapeutic dose. Athena GTX will be supplying wearable WatchDawg™? monitoring and cloud-based acquisition of data through partners at Verizon, to supply objective data on the relief of symptoms to both the participants and physicians/care teams. The company expects a full data presentation for a large and heretofore patient problem that was very difficult to manage. This will be one of two studies with which the company are engaged, with a subsequent well-funded study on PTSD, alcohol use disorder, and suicidal ideation, with an end goal to reduce suicide to be announced shortly. To get the latest on the exciting developments by the Halberd/Athena teams, subscribe by submitting this form. The partnership involves the use of pharmaceuticals, nutraceuticals, yoga/meditation, unique, wearable monitoring, and psychological therapists combining to service veteran mental health issues and suicidal ideation.お知らせ • Dec 03Halberd Corporation Update on Watchdawg®? Ptsd TreatmentHalberd Corporation previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting improvements have been incorporated into future studies. The next phase to be conducted on the patent-pending medicines/procedures is a 100-person study which will be conducted in sub-groups as volunteers are identified and qualified. The initial sub-group of 10 volunteers of this 100-person study have been selected. Results from this sub-group should be available around mid-January.お知らせ • Oct 01Halberd & Athena GTX Report Initial Success of WatchDawg®? PTSD Treatment Pilot StudyHalberd Corporation released the results of the recently completed WatchDawg®? Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wear a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participants data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health. During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.お知らせ • Jul 24Halberd Corporation's Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test ResultsHalberd Corporation announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-Ax™ nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. These results are very encouraging to point of injury (POI) care. Administration of this novel TBI therapeutic translates to the potential of buddy care or self-administration via a developing auto-nasal injector under development at Halberd’s partner Athena GTX.お知らせ • May 03Halberd Announces Patented LDN+ Drug Has Begun Pre-Pilot Trials with Military VeteransHalberd Corporation announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot study demographic of thirty (30) participants, followed by a significantly larger safety study of 150 participants in the coming weeks. The military has a significant Post Traumatic Stress Disorder (PTSD) and suicide ideation problem and is actively seeking solutions. Halberd's LDN+ drug acts as an antagonist against chemical and alcohol use disorder (AUD) and is uniquely formulated to relieve pain and anxiety associated PTSD and suicidal ideation. Additional details will be released as the clinical trial progresses. These studies include not only the patented pharmaceutical but 24/7 wearable physiological and psychological monitoring of all participants and the opportunity for each participant to engage in adjunct therapies.最新情報をもっと見るRecent updatesお知らせ • Oct 27Halberd Corporation Successfully Demonstrates Its Proprietary Breakthrough AI Technology for Behavioral Analysis PlatformHalberd Corporation announced the successful completion of a technical feasibility demonstration for NeuroSense AI, its proprietary behavioral intelligence platform in development. The live demonstration, conducted Thursday before key stakeholders, validated the platform's core technological approach and confirmed the feasibility of multi-modal behavioral analysis employing advanced artificial intelligence. In a live demonstration before clinical advisors and company leadership, the NeuroSense AI development team successfully showcased the platform's capacity to: Capture and process real-time behavioral data with professional-grade accuracy; Extract multiple behavioral features simultaneously (vocal patterns, energy levels, temporal characteristics); Generate automated behavioral assessments and visualizations; Demonstrate integration readiness with Claude AI for advanced pattern interpretation and capacity to demonstrate deviations from pre-establish norms. Technology Validation Milestone: The successful demonstration represents a critical development milestone, confirming that: Core Technologies Are Proven: The platform leverages commercially available, enterprise-grade technologies including Claude AI (Anthropic), industry-standard audio processing libraries, and cloud-native architecture patterns. Real-Time Processing Works: The system demonstrated capability to process behavioral data and generate analysis in real-time, a critical requirement for continuous monitoring applications.お知らせ • May 28Halberd Corporation & Athena Telemedicine Partnership, LLC Announce Clinical Study UpdatesHalberd Corporation in cooperation with Athena Telemedicine Partners, LLC, announced astounding clinical efficacy for patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease. previously found that patent-pending LDX medication is an incredibly ubiquitous compound that has powerful applications in the management of addiction, chronic inflammatory disorders, neurological disorders, pain management and represents a multibillion-dollar market potential. The problem: As of recent estimates, approximately 850 million people worldwide suffer from some form of kidney disease, including chronic kidney disease (CKD), acute kidney injury (AKI), and end-stage kidney failure. International Society of Nephrology Chronic Kidney Disease (CKD): In 2021, there were approximately 673.7 million cases of CKD globally. CKD is characterized by abnormalities in kidney structure or function lasting for more than three months and is a leading cause of kidney failure. Frontiers. Unresponsive to large doses of multiple medications, including Gabapentin, she was placed on LDX and a custom CBD nutraceutical. For the first time in five years, she became almost immediately symptom free. However, LD stopped the LDX based on physician input, and had a recurrence of her symptoms. She was hospitalized for hypertension and stabilized, a significant reduction in medications prescribed ensued, including Gabapentin, and as a result her neuropathy and pruritic symptoms reappeared. She was started on LDX again, but under a titrated dose response protocol that is patent pending, and immediately found relief of both the pain and itching. The company will be offering a 90-day trial for clinicians dealing with dialysis patients on a safety and proof of efficacy FDA study for LDX. platform involves a very low dose initiation and progressive introduction of LDN and methocarbamol with natural cinnamon as a filler to a traditional therapeutic dose. Athena GTX will be supplying wearable WatchDawg™? monitoring and cloud-based acquisition of data through partners at Verizon, to supply objective data on the relief of symptoms to both the participants and physicians/care teams. The company expects a full data presentation for a large and heretofore patient problem that was very difficult to manage. This will be one of two studies with which the company are engaged, with a subsequent well-funded study on PTSD, alcohol use disorder, and suicidal ideation, with an end goal to reduce suicide to be announced shortly. To get the latest on the exciting developments by the Halberd/Athena teams, subscribe by submitting this form. The partnership involves the use of pharmaceuticals, nutraceuticals, yoga/meditation, unique, wearable monitoring, and psychological therapists combining to service veteran mental health issues and suicidal ideation.お知らせ • Dec 03Halberd Corporation Update on Watchdawg®? Ptsd TreatmentHalberd Corporation previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting improvements have been incorporated into future studies. The next phase to be conducted on the patent-pending medicines/procedures is a 100-person study which will be conducted in sub-groups as volunteers are identified and qualified. The initial sub-group of 10 volunteers of this 100-person study have been selected. Results from this sub-group should be available around mid-January.お知らせ • Oct 01Halberd & Athena GTX Report Initial Success of WatchDawg®? PTSD Treatment Pilot StudyHalberd Corporation released the results of the recently completed WatchDawg®? Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wear a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participants data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health. During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.お知らせ • Jul 24Halberd Corporation's Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test ResultsHalberd Corporation announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-Ax™ nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. These results are very encouraging to point of injury (POI) care. Administration of this novel TBI therapeutic translates to the potential of buddy care or self-administration via a developing auto-nasal injector under development at Halberd’s partner Athena GTX.お知らせ • May 03Halberd Announces Patented LDN+ Drug Has Begun Pre-Pilot Trials with Military VeteransHalberd Corporation announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot study demographic of thirty (30) participants, followed by a significantly larger safety study of 150 participants in the coming weeks. The military has a significant Post Traumatic Stress Disorder (PTSD) and suicide ideation problem and is actively seeking solutions. Halberd's LDN+ drug acts as an antagonist against chemical and alcohol use disorder (AUD) and is uniquely formulated to relieve pain and anxiety associated PTSD and suicidal ideation. Additional details will be released as the clinical trial progresses. These studies include not only the patented pharmaceutical but 24/7 wearable physiological and psychological monitoring of all participants and the opportunity for each participant to engage in adjunct therapies.お知らせ • Apr 05Halberd Corporation's Patented Drug, LDN+ Drug Enters Significant Safety Trial Protocol Under a CRADA Contract for Military Active Duty and VeteransHalberd Corporation's Patented LDN+ Drug has an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd Corporation's patented drug, LDN+, a combination of low-dose Naltrexone and Cyclobenzaprine, is a central part of a just executed Cooperative Research and Development Agreement (CRADA) contract in conjunction with the Exalted Warrior Foundation out of Tampa Florida and three other companies. The six-week safety study subjects will be current active-duty and retired military volunteers for a period of six weeks beginning immediately after execution of Institutional Review Board (IRB) Approval. Halberd's patented LDN+ drug uniquely combines drugs previously approved by the FDA and widely used both individually and in a compounded formulation for many years. In combination, the drugs are believed to act as an antagonist against chemical and alcohol addiction and to relieve pain and anxiety linked to more severe mental health issues facing military today. Pending the results of this limited pilot safety trial, and the results anticipated, higher volumes and more extensive tests of military personnel and veterans will be launched in less than 2 months. The clear pathway forward is to then obtain FDA clearance for the combined new pharmaceutical.お知らせ • Feb 09Halberd and Mississippi State University to Commence Stage Ii Advanced Tbi Nasal Spray TestingHalberd Corporation's Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) were approved by the Institutional Animal Care and Use Committee. Dr. Russell Carr, the Primary Investigator, initiated preparations for this extension of the successful Phase #1 pilot test program, completed last year with demonstrably compelling results. The advanced program will launch promptly. Numerous federal agencies expressed enthusiasm for the pursuit.お知らせ • Sep 07Halberd Corporation Announces Astounding Early Test Results of Traumatic Brain Injury Project At Mississippi State UniversityHalberd Corporation's research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd's patent-pending nasal spray to mitigate the effects of TBI. Neuron Specific Enolase (NSE) is a biomarker of neuronal damage that has been shown to be a predictor of the ultimate outcomes of TBI. Glial Fibrillary Acid Protein (GFAP) is an indicator of the induction of neuroinflammation and is increased following traumatic brain injury. It is also thought to be an indicator of ongoing neurodegeneration related to numerous other diseases, Reductions of NSE and GFAP are associated with better neurological outcomes from head trauma.お知らせ • Aug 23Halberd Corporation's Successful Completion of Sampling Phase Marks Major Milestone for Project At Mississippi State UniversityHalberd Corporation announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model to study endpoints for Halberd's patent-pending nasal spray's ability to mitigate the effects of traumatic brain injury (TBI). The analysis of these tissue samples can now proceed to examine and quantify the presence of certain markers related to brain damage and to assess the effectiveness of the nasal spray treatment. The nasal spray is designed to eliminate the otherwise inevitable and irreversible negative effects of TBI by directly targeting the associated antigens in cerebrospinal fluid (CSF). Halberd's nasal spray employs a patent-pending blend of three active ingredients designed to timely address and block the excess production of certain identified inflammatory cytokines and neurotransmitters triggered by head trauma. Excess quantities of these elements are associated with irreversible brain injury. The testing at MSU will evaluate the importance of the timely application of Halberd's nasal spray within hours of a traumatic brain injury to mitigate the otherwise inevitable long-term neurodegeneraton often leading to not just TBI, but also to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc. Halberd's early treatment nasal spray product has the potential for wide acceptance by contact sports participants, first responders, trauma centers and the military. Following successful completion of these pre-clinical tests, Halberd intends to immediately seek expeditious approval of the treatment by the FDA and other regulatory bodies throughout the world to enable sale and distribution within the United States as well as other potential world markets. As previously reported, Halberd has already engaged experts for this pursuit with the FDA.お知らせ • Feb 14Halberd Corporation Announces Breakthrough in Candida Auris TreatmentHalberd Corporation announced a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing. With its scientific partner, Halberd has developed a novel, extracorporeal method of successfully eradicating the multidrug-resistant pathogen using a tuned laser in conjunction with metallic nanoparticles conjugated to a patent-pending non-neutralizing, high-affinity antibody. Halberd previously demonstrated its patent-pending extracorporeal laser eradication by successfully eliminating Escherichia coli and antibiotic resistant strains of Gram-Negative bacteria. Candida auris is a serious and growing public health threat. It is a multidrug-resistant fungal pathogen that can cause serious infections and is associated with high mortality rates, particularly in immunocompromised patients.お知らせ • Feb 01Halberd to Conduct Animal Tests of Nasal Spray That Blocks Negative Effects of Head TraumaHalberd Corporation confirmed that animal testing at Mississippi State University will focus on Halberd's patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury. The work will be conducted over the next several months under the direction of Dr. RussellCarr, of the College of Veterinary Medicine. Following Halberd's in vitro successful eradication of each known antigen associated with head trauma, including TBI, in collaboration with Youngstown State University, in vivo studies are to commence at Mississippi State University. Funding for the program has already been approved. Head trauma initiates a cascade of overproduction of certain proteins and inflammatory cytokines in the brain. This overproduction, depending on the magnitude of the injury, often manifests itself in neurological changes in behavior, such as PTSD, aggression and suicide ideation. Halberd's triple-action nasal spray is designed to counteract these TBI-related complications by blocking the overproduction mechanism and allowing the brain to recover naturally. The benefits of such an approach in treating head injuries to military personnel, contact sports athletes and ordinary people who experience head trauma are monumental.お知らせ • Jan 25Halberd Corporation Agrees to Animal Testing at Mississippi State UniversityHalberd Corporation has agreed to conduct animal testing at Mississippi State University's (MSU) animal testing laboratory. The Department of Comparative Biomedical Sciences in the College of Veterinary Medicine and the Department of Biomedical Engineering at Mississippi State University will be working with Halberd Corporation on an upcoming research project. The project will be investigating the effectiveness of novel therapeutic measures that are under development for combating the damaging effects of traumatic brain injury.お知らせ • Nov 18Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint by Eradicating Cancer Disease Antigen Linked to Breast CancerHalberd Corporation announced that researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 through the use of laser emissive energy in their latest series of tests. Halberd had been successful previously in eradicating all five cancer disease antigens (PD-1, PDL-1, IL-6, TNF-Alpha, and CTLA-4) attempted to date in a matter of less than 10 minutes exposure to laser emissive energy using Halberd's patent-pending process in conjunction with antibodies conjoined with proprietary nanoparticles. Halberd plans to demonstrate successful eradication of the remaining BTLA cancer disease antigen in near-term scheduled testing.お知らせ • Nov 01Halberd Corporation announced delayed annual 10-K filingOn 10/31/2022, Halberd Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Oct 13Halberd Corporation Progresses from Eliminating Top Brain Disease Antigens from CSF to Eradication of Interleukin-6 from Human Blood SerumHalberd Corporation demonstrated the removal of Interleukin-6 (IL-6) from human blood serum during in-vitro laboratory studies. Excess Interleukin-6 in the blood has been linked to numerous adverse health conditions. Unlike Halberd's earlier successful experiments, which eliminated IL-6 from cerebrospinal fluid (CSF) through exposure to laser irradiation, this recent experiment used an engineered antibody with a strong binding affinity to IL-6 which was chemically bonded to a medical grade microbead filter.株主還元HALBUS BiotechsUS 市場7D29.4%-1.6%-0.9%1Y-54.2%34.4%24.4%株主還元を見る業界別リターン: HALB過去 1 年間で34.4 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: HALBは、過去 1 年間で24.4 % のリターンを上げたUS市場を下回りました。価格変動Is HALB's price volatile compared to industry and market?HALB volatilityHALB Average Weekly Movement21.3%Biotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.1%安定した株価: HALBの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: HALBの weekly volatility ( 21% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2009n/aWilliam Hartmanhalberdcorporation.comバイオテクノロジー企業であるハルバード・コーポレーションは、神経変性疾患の治療薬を開発している。外傷後ストレス障害／慢性外傷性脳症、アルツハイマー病、パーキンソン病、がん、血液媒介性疾患、脳脊髄液関連疾患の治療薬を提供している。同社は2009年に法人化され、ペンシルベニア州ジャクソン・センターを拠点としている。もっと見るHalberd Corporation 基礎のまとめHalberd の収益と売上を時価総額と比較するとどうか。HALB 基礎統計学時価総額US$822.03k収益（TTM）-US$1.71m売上高(TTM)US$6.94k0.0xP/Sレシオ0.0xPER（株価収益率HALB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計HALB 損益計算書（TTM）収益US$6.94k売上原価US$2.44k売上総利益US$4.50kその他の費用US$1.71m収益-US$1.71m直近の収益報告Apr 30, 2022次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%HALB の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/15 07:53終値2026/05/15 00:00収益2022/04/30年間収益2021/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Halberd Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Oct 27Halberd Corporation Successfully Demonstrates Its Proprietary Breakthrough AI Technology for Behavioral Analysis PlatformHalberd Corporation announced the successful completion of a technical feasibility demonstration for NeuroSense AI, its proprietary behavioral intelligence platform in development. The live demonstration, conducted Thursday before key stakeholders, validated the platform's core technological approach and confirmed the feasibility of multi-modal behavioral analysis employing advanced artificial intelligence. In a live demonstration before clinical advisors and company leadership, the NeuroSense AI development team successfully showcased the platform's capacity to: Capture and process real-time behavioral data with professional-grade accuracy; Extract multiple behavioral features simultaneously (vocal patterns, energy levels, temporal characteristics); Generate automated behavioral assessments and visualizations; Demonstrate integration readiness with Claude AI for advanced pattern interpretation and capacity to demonstrate deviations from pre-establish norms. Technology Validation Milestone: The successful demonstration represents a critical development milestone, confirming that: Core Technologies Are Proven: The platform leverages commercially available, enterprise-grade technologies including Claude AI (Anthropic), industry-standard audio processing libraries, and cloud-native architecture patterns. Real-Time Processing Works: The system demonstrated capability to process behavioral data and generate analysis in real-time, a critical requirement for continuous monitoring applications.
お知らせ • May 28Halberd Corporation & Athena Telemedicine Partnership, LLC Announce Clinical Study UpdatesHalberd Corporation in cooperation with Athena Telemedicine Partners, LLC, announced astounding clinical efficacy for patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease. previously found that patent-pending LDX medication is an incredibly ubiquitous compound that has powerful applications in the management of addiction, chronic inflammatory disorders, neurological disorders, pain management and represents a multibillion-dollar market potential. The problem: As of recent estimates, approximately 850 million people worldwide suffer from some form of kidney disease, including chronic kidney disease (CKD), acute kidney injury (AKI), and end-stage kidney failure. International Society of Nephrology Chronic Kidney Disease (CKD): In 2021, there were approximately 673.7 million cases of CKD globally. CKD is characterized by abnormalities in kidney structure or function lasting for more than three months and is a leading cause of kidney failure. Frontiers. Unresponsive to large doses of multiple medications, including Gabapentin, she was placed on LDX and a custom CBD nutraceutical. For the first time in five years, she became almost immediately symptom free. However, LD stopped the LDX based on physician input, and had a recurrence of her symptoms. She was hospitalized for hypertension and stabilized, a significant reduction in medications prescribed ensued, including Gabapentin, and as a result her neuropathy and pruritic symptoms reappeared. She was started on LDX again, but under a titrated dose response protocol that is patent pending, and immediately found relief of both the pain and itching. The company will be offering a 90-day trial for clinicians dealing with dialysis patients on a safety and proof of efficacy FDA study for LDX. platform involves a very low dose initiation and progressive introduction of LDN and methocarbamol with natural cinnamon as a filler to a traditional therapeutic dose. Athena GTX will be supplying wearable WatchDawg™? monitoring and cloud-based acquisition of data through partners at Verizon, to supply objective data on the relief of symptoms to both the participants and physicians/care teams. The company expects a full data presentation for a large and heretofore patient problem that was very difficult to manage. This will be one of two studies with which the company are engaged, with a subsequent well-funded study on PTSD, alcohol use disorder, and suicidal ideation, with an end goal to reduce suicide to be announced shortly. To get the latest on the exciting developments by the Halberd/Athena teams, subscribe by submitting this form. The partnership involves the use of pharmaceuticals, nutraceuticals, yoga/meditation, unique, wearable monitoring, and psychological therapists combining to service veteran mental health issues and suicidal ideation.
お知らせ • Dec 03Halberd Corporation Update on Watchdawg®? Ptsd TreatmentHalberd Corporation previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting improvements have been incorporated into future studies. The next phase to be conducted on the patent-pending medicines/procedures is a 100-person study which will be conducted in sub-groups as volunteers are identified and qualified. The initial sub-group of 10 volunteers of this 100-person study have been selected. Results from this sub-group should be available around mid-January.
お知らせ • Oct 01Halberd & Athena GTX Report Initial Success of WatchDawg®? PTSD Treatment Pilot StudyHalberd Corporation released the results of the recently completed WatchDawg®? Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wear a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participants data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health. During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.
お知らせ • Jul 24Halberd Corporation's Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test ResultsHalberd Corporation announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-Ax™ nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. These results are very encouraging to point of injury (POI) care. Administration of this novel TBI therapeutic translates to the potential of buddy care or self-administration via a developing auto-nasal injector under development at Halberd’s partner Athena GTX.
お知らせ • May 03Halberd Announces Patented LDN+ Drug Has Begun Pre-Pilot Trials with Military VeteransHalberd Corporation announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot study demographic of thirty (30) participants, followed by a significantly larger safety study of 150 participants in the coming weeks. The military has a significant Post Traumatic Stress Disorder (PTSD) and suicide ideation problem and is actively seeking solutions. Halberd's LDN+ drug acts as an antagonist against chemical and alcohol use disorder (AUD) and is uniquely formulated to relieve pain and anxiety associated PTSD and suicidal ideation. Additional details will be released as the clinical trial progresses. These studies include not only the patented pharmaceutical but 24/7 wearable physiological and psychological monitoring of all participants and the opportunity for each participant to engage in adjunct therapies.
お知らせ • Oct 27Halberd Corporation Successfully Demonstrates Its Proprietary Breakthrough AI Technology for Behavioral Analysis PlatformHalberd Corporation announced the successful completion of a technical feasibility demonstration for NeuroSense AI, its proprietary behavioral intelligence platform in development. The live demonstration, conducted Thursday before key stakeholders, validated the platform's core technological approach and confirmed the feasibility of multi-modal behavioral analysis employing advanced artificial intelligence. In a live demonstration before clinical advisors and company leadership, the NeuroSense AI development team successfully showcased the platform's capacity to: Capture and process real-time behavioral data with professional-grade accuracy; Extract multiple behavioral features simultaneously (vocal patterns, energy levels, temporal characteristics); Generate automated behavioral assessments and visualizations; Demonstrate integration readiness with Claude AI for advanced pattern interpretation and capacity to demonstrate deviations from pre-establish norms. Technology Validation Milestone: The successful demonstration represents a critical development milestone, confirming that: Core Technologies Are Proven: The platform leverages commercially available, enterprise-grade technologies including Claude AI (Anthropic), industry-standard audio processing libraries, and cloud-native architecture patterns. Real-Time Processing Works: The system demonstrated capability to process behavioral data and generate analysis in real-time, a critical requirement for continuous monitoring applications.
お知らせ • May 28Halberd Corporation & Athena Telemedicine Partnership, LLC Announce Clinical Study UpdatesHalberd Corporation in cooperation with Athena Telemedicine Partners, LLC, announced astounding clinical efficacy for patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease. previously found that patent-pending LDX medication is an incredibly ubiquitous compound that has powerful applications in the management of addiction, chronic inflammatory disorders, neurological disorders, pain management and represents a multibillion-dollar market potential. The problem: As of recent estimates, approximately 850 million people worldwide suffer from some form of kidney disease, including chronic kidney disease (CKD), acute kidney injury (AKI), and end-stage kidney failure. International Society of Nephrology Chronic Kidney Disease (CKD): In 2021, there were approximately 673.7 million cases of CKD globally. CKD is characterized by abnormalities in kidney structure or function lasting for more than three months and is a leading cause of kidney failure. Frontiers. Unresponsive to large doses of multiple medications, including Gabapentin, she was placed on LDX and a custom CBD nutraceutical. For the first time in five years, she became almost immediately symptom free. However, LD stopped the LDX based on physician input, and had a recurrence of her symptoms. She was hospitalized for hypertension and stabilized, a significant reduction in medications prescribed ensued, including Gabapentin, and as a result her neuropathy and pruritic symptoms reappeared. She was started on LDX again, but under a titrated dose response protocol that is patent pending, and immediately found relief of both the pain and itching. The company will be offering a 90-day trial for clinicians dealing with dialysis patients on a safety and proof of efficacy FDA study for LDX. platform involves a very low dose initiation and progressive introduction of LDN and methocarbamol with natural cinnamon as a filler to a traditional therapeutic dose. Athena GTX will be supplying wearable WatchDawg™? monitoring and cloud-based acquisition of data through partners at Verizon, to supply objective data on the relief of symptoms to both the participants and physicians/care teams. The company expects a full data presentation for a large and heretofore patient problem that was very difficult to manage. This will be one of two studies with which the company are engaged, with a subsequent well-funded study on PTSD, alcohol use disorder, and suicidal ideation, with an end goal to reduce suicide to be announced shortly. To get the latest on the exciting developments by the Halberd/Athena teams, subscribe by submitting this form. The partnership involves the use of pharmaceuticals, nutraceuticals, yoga/meditation, unique, wearable monitoring, and psychological therapists combining to service veteran mental health issues and suicidal ideation.
お知らせ • Dec 03Halberd Corporation Update on Watchdawg®? Ptsd TreatmentHalberd Corporation previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting improvements have been incorporated into future studies. The next phase to be conducted on the patent-pending medicines/procedures is a 100-person study which will be conducted in sub-groups as volunteers are identified and qualified. The initial sub-group of 10 volunteers of this 100-person study have been selected. Results from this sub-group should be available around mid-January.
お知らせ • Oct 01Halberd & Athena GTX Report Initial Success of WatchDawg®? PTSD Treatment Pilot StudyHalberd Corporation released the results of the recently completed WatchDawg®? Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wear a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participants data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health. During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.
お知らせ • Jul 24Halberd Corporation's Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test ResultsHalberd Corporation announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-Ax™ nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. These results are very encouraging to point of injury (POI) care. Administration of this novel TBI therapeutic translates to the potential of buddy care or self-administration via a developing auto-nasal injector under development at Halberd’s partner Athena GTX.
お知らせ • May 03Halberd Announces Patented LDN+ Drug Has Begun Pre-Pilot Trials with Military VeteransHalberd Corporation announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot study demographic of thirty (30) participants, followed by a significantly larger safety study of 150 participants in the coming weeks. The military has a significant Post Traumatic Stress Disorder (PTSD) and suicide ideation problem and is actively seeking solutions. Halberd's LDN+ drug acts as an antagonist against chemical and alcohol use disorder (AUD) and is uniquely formulated to relieve pain and anxiety associated PTSD and suicidal ideation. Additional details will be released as the clinical trial progresses. These studies include not only the patented pharmaceutical but 24/7 wearable physiological and psychological monitoring of all participants and the opportunity for each participant to engage in adjunct therapies.
お知らせ • Apr 05Halberd Corporation's Patented Drug, LDN+ Drug Enters Significant Safety Trial Protocol Under a CRADA Contract for Military Active Duty and VeteransHalberd Corporation's Patented LDN+ Drug has an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd Corporation's patented drug, LDN+, a combination of low-dose Naltrexone and Cyclobenzaprine, is a central part of a just executed Cooperative Research and Development Agreement (CRADA) contract in conjunction with the Exalted Warrior Foundation out of Tampa Florida and three other companies. The six-week safety study subjects will be current active-duty and retired military volunteers for a period of six weeks beginning immediately after execution of Institutional Review Board (IRB) Approval. Halberd's patented LDN+ drug uniquely combines drugs previously approved by the FDA and widely used both individually and in a compounded formulation for many years. In combination, the drugs are believed to act as an antagonist against chemical and alcohol addiction and to relieve pain and anxiety linked to more severe mental health issues facing military today. Pending the results of this limited pilot safety trial, and the results anticipated, higher volumes and more extensive tests of military personnel and veterans will be launched in less than 2 months. The clear pathway forward is to then obtain FDA clearance for the combined new pharmaceutical.
お知らせ • Feb 09Halberd and Mississippi State University to Commence Stage Ii Advanced Tbi Nasal Spray TestingHalberd Corporation's Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) were approved by the Institutional Animal Care and Use Committee. Dr. Russell Carr, the Primary Investigator, initiated preparations for this extension of the successful Phase #1 pilot test program, completed last year with demonstrably compelling results. The advanced program will launch promptly. Numerous federal agencies expressed enthusiasm for the pursuit.
お知らせ • Sep 07Halberd Corporation Announces Astounding Early Test Results of Traumatic Brain Injury Project At Mississippi State UniversityHalberd Corporation's research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd's patent-pending nasal spray to mitigate the effects of TBI. Neuron Specific Enolase (NSE) is a biomarker of neuronal damage that has been shown to be a predictor of the ultimate outcomes of TBI. Glial Fibrillary Acid Protein (GFAP) is an indicator of the induction of neuroinflammation and is increased following traumatic brain injury. It is also thought to be an indicator of ongoing neurodegeneration related to numerous other diseases, Reductions of NSE and GFAP are associated with better neurological outcomes from head trauma.
お知らせ • Aug 23Halberd Corporation's Successful Completion of Sampling Phase Marks Major Milestone for Project At Mississippi State UniversityHalberd Corporation announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model to study endpoints for Halberd's patent-pending nasal spray's ability to mitigate the effects of traumatic brain injury (TBI). The analysis of these tissue samples can now proceed to examine and quantify the presence of certain markers related to brain damage and to assess the effectiveness of the nasal spray treatment. The nasal spray is designed to eliminate the otherwise inevitable and irreversible negative effects of TBI by directly targeting the associated antigens in cerebrospinal fluid (CSF). Halberd's nasal spray employs a patent-pending blend of three active ingredients designed to timely address and block the excess production of certain identified inflammatory cytokines and neurotransmitters triggered by head trauma. Excess quantities of these elements are associated with irreversible brain injury. The testing at MSU will evaluate the importance of the timely application of Halberd's nasal spray within hours of a traumatic brain injury to mitigate the otherwise inevitable long-term neurodegeneraton often leading to not just TBI, but also to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc. Halberd's early treatment nasal spray product has the potential for wide acceptance by contact sports participants, first responders, trauma centers and the military. Following successful completion of these pre-clinical tests, Halberd intends to immediately seek expeditious approval of the treatment by the FDA and other regulatory bodies throughout the world to enable sale and distribution within the United States as well as other potential world markets. As previously reported, Halberd has already engaged experts for this pursuit with the FDA.
お知らせ • Feb 14Halberd Corporation Announces Breakthrough in Candida Auris TreatmentHalberd Corporation announced a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing. With its scientific partner, Halberd has developed a novel, extracorporeal method of successfully eradicating the multidrug-resistant pathogen using a tuned laser in conjunction with metallic nanoparticles conjugated to a patent-pending non-neutralizing, high-affinity antibody. Halberd previously demonstrated its patent-pending extracorporeal laser eradication by successfully eliminating Escherichia coli and antibiotic resistant strains of Gram-Negative bacteria. Candida auris is a serious and growing public health threat. It is a multidrug-resistant fungal pathogen that can cause serious infections and is associated with high mortality rates, particularly in immunocompromised patients.
お知らせ • Feb 01Halberd to Conduct Animal Tests of Nasal Spray That Blocks Negative Effects of Head TraumaHalberd Corporation confirmed that animal testing at Mississippi State University will focus on Halberd's patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury. The work will be conducted over the next several months under the direction of Dr. RussellCarr, of the College of Veterinary Medicine. Following Halberd's in vitro successful eradication of each known antigen associated with head trauma, including TBI, in collaboration with Youngstown State University, in vivo studies are to commence at Mississippi State University. Funding for the program has already been approved. Head trauma initiates a cascade of overproduction of certain proteins and inflammatory cytokines in the brain. This overproduction, depending on the magnitude of the injury, often manifests itself in neurological changes in behavior, such as PTSD, aggression and suicide ideation. Halberd's triple-action nasal spray is designed to counteract these TBI-related complications by blocking the overproduction mechanism and allowing the brain to recover naturally. The benefits of such an approach in treating head injuries to military personnel, contact sports athletes and ordinary people who experience head trauma are monumental.
お知らせ • Jan 25Halberd Corporation Agrees to Animal Testing at Mississippi State UniversityHalberd Corporation has agreed to conduct animal testing at Mississippi State University's (MSU) animal testing laboratory. The Department of Comparative Biomedical Sciences in the College of Veterinary Medicine and the Department of Biomedical Engineering at Mississippi State University will be working with Halberd Corporation on an upcoming research project. The project will be investigating the effectiveness of novel therapeutic measures that are under development for combating the damaging effects of traumatic brain injury.
お知らせ • Nov 18Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint by Eradicating Cancer Disease Antigen Linked to Breast CancerHalberd Corporation announced that researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 through the use of laser emissive energy in their latest series of tests. Halberd had been successful previously in eradicating all five cancer disease antigens (PD-1, PDL-1, IL-6, TNF-Alpha, and CTLA-4) attempted to date in a matter of less than 10 minutes exposure to laser emissive energy using Halberd's patent-pending process in conjunction with antibodies conjoined with proprietary nanoparticles. Halberd plans to demonstrate successful eradication of the remaining BTLA cancer disease antigen in near-term scheduled testing.
お知らせ • Nov 01Halberd Corporation announced delayed annual 10-K filingOn 10/31/2022, Halberd Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Oct 13Halberd Corporation Progresses from Eliminating Top Brain Disease Antigens from CSF to Eradication of Interleukin-6 from Human Blood SerumHalberd Corporation demonstrated the removal of Interleukin-6 (IL-6) from human blood serum during in-vitro laboratory studies. Excess Interleukin-6 in the blood has been linked to numerous adverse health conditions. Unlike Halberd's earlier successful experiments, which eliminated IL-6 from cerebrospinal fluid (CSF) through exposure to laser irradiation, this recent experiment used an engineered antibody with a strong binding affinity to IL-6 which was chemically bonded to a medical grade microbead filter.
